Eric Van Cutsem

Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆

David Tougeron, Jianming Xu, E. Raymond, R. Hubner et autres

fr, cn, gb, jp, pl, be, kr, es, it, us, de (code pays fourni par la source)

Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

Solange Peters, May‐Lucie Meyer, F. André, Guillem Argilés et autres

ch, fr, us, gb, nl, it, de, es, gr, be, au (code pays fourni par la source)

Table 4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Data from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Supplementary Materials from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Table S1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Figure 1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Table S2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Table 3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Table 1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Figure S1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres

Table S6 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings

James J. Harding, Ralf‐Dieter Hofheinz, Elena Élez, Yasutoshi Kuboki et autres